Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
But launch is unlikely before 2024.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Welcome to the calm before the Covid-19 storm.
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.